Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Physiology 20: 357-365, 2005; doi:10.1152/physiol.00030.2005
1548-9213/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sinclair, E. M
Right arrow Articles by Drucker, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinclair, E. M
Right arrow Articles by Drucker, D. J.
Physiology, Vol. 20, No. 5, 357-365, October 2005
© 2005 Int. Union Physiol. Sci./Am. Physiol. Soc.

REVIEW

Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential

Elaine M Sinclair and Daniel J. Drucker

Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital and the University of Toronto, Toronto, Ontario, Canada

d.drucker{at}utoronto.ca

Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.




This article has been cited by other articles:


Home page
 J EndocrinolHome page
T. Jin
Mechanisms underlying proglucagon gene expression
J. Endocrinol., July 1, 2008; 198(1): 17 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev, October 1, 2007; 87(4): 1409 - 1439.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the Int. Union Physiol. Sci./Am. Physiol. Soc.